Hereditary hemorrhagic telangiectasia (HHT) (MIM 187300) is an autosomal dominant vascular dysplasia with the following characteristics: epistaxes and telangiectases are present in more than 95% of patients 1, 2 ; telangiectases involve the skin and mucosae (causing epistaxes and gastrointestinal bleeding that may be severe enough to require transfusions); visceral arteriovenous malformations (AVMs) are mainly observed in the liver (57% of patients), lungs (34%), and brain (9.7%) 2 and may cause severe life-threatening complications. Neurologic complications (strokes, cerebral abscesses, seizures) may be prevented with appropriate treatment of pulmonary AVMs.
The diagnosis of HHT can be confirmed, according to Curaçao's criteria, 3 when three of the four suggested diagnostic criteria (epistaxes, telangiectases, visceral lesions, first-degree affected relative) are present. The phenotype is highly variable, and penetrance is usually complete by the age of 40 years. 1 Approximately 80% of patients with HHT carry mutations in either of two genes: Endoglin (ENG, OMIM 131195) (HHT1) or activin receptor-like kinase 1 (ACVRL1, OMIM 601284) (HHT2). 4, 5 Evidence for a third locus has also been reported. 6, 7 Association of the HHT phenotype with juvenile polyposis and mutations in the MADH4 gene have recently been demonstrated 8 as well.
Pulmonary arterial hypertension (PAH) is a progressive disorder in which an increased pulmonary vascular resistance is caused by occlusion of the smallest pulmonary arteries; subsequently, right ventricular failure may occur. 9 A diagnosis of idiopathic pulmonary hypertension is proposed when PAH is observed in the absence of any known predisposing condition such as pulmonary embolism, connective tissue disease, and lung or heart disease. Women are affected twice as commonly as men. The familial form of "primary pulmonary hypertension" (OMIM 178600) is observed in approximately 10% of overall cases. 10 It is rare, with an incidence of approximately 1 in 100,000 to 1 in 1,000,000, and inherited as an autosomal dominant trait with reduced penetrance; genetic anticipation was discussed by Deng et al. in 2000. 11 Finally, mutations in the BMPR2 have also been identified. 12 A form of PAH that is clinically and histologically indistinguishable from idiopathic pulmonary hypertension may occur in patients with HHT. In 2001, Trembath et al. 13 demonstrated mutations in the ACVRL1 gene in patients who showed clinical features of both PAH and HHT; this observation was subsequently confirmed by other studies. 14, 15 All of these studies were carried out in patients (or families) with a known history of PAH in whom symptoms of HHT could also be identified; the mutations that have been identified are summarized in Table 1 .
We studied a group of 68 subjects affected by HHT who did not display any clinical evidence of PAH to assess pulmonary artery systolic pressure (PASP) values. We were interested in the possible increase of PASP values, as well as in the frequency of the increase, and in correlating, if possible, elevated PASP with genotype.
MATERIALS AND METHODS

Patients
With Doppler transthoracic echocardiography (TTE), 68 consecutive patients (32 females) from 48 different families were screened, previously diagnosed with HHT by C.D., E.B., and F.P., according to Curaçao's criteria. 3 None of the subjects studied had a personal clinical history suggesting PAH; cases 10 to 16 (Table 2) belong to a family with a known history of PAH in a single relative who was not included in the present study; the relatives tested were selected on the basis of HHT diagnostic criteria only.
In case 1 (Table 2) , PAH was judged to be secondary to a mitral valve disease, whereas none of the other patients demonstrated any known risk factors (systemic disorders or exposure to chemicals). Six additional patients with HHT, known carriers of exon 10 mutations who were not included in the original group of 68, were studied in Lyon by B.M.
Doppler transthoracic echocardiography
Echocardiographic studies were performed on all patients using standard M-mode, two-dimensional, and Doppler echocardiographic evaluations. A commercially available GE-Vingmed ultrasound (System Five) (Horten, Norway) instrument and a 2.5 to 3.5 phased-array transducer were adopted for cardiac imaging, pulsed-and continuous-wave Doppler, and measurement of pulmonary pressure. A contrast echocardiographic study for verifying the presence of pulmonary AVMs was also performed in each patient. The Doppler method used for the evaluation of systolic pulmonary artery pressures is described in detail in a previous study. 16 Measurements represent an average of three normal sinus rhythm beats. Pulsed-and continuous-wave Doppler echocardiographic velocity tracings were recorded on paper strip charts at a speed of 100 mm/sec.
Contrast echocardiography was performed in all patients according to Nanthakumar et al. 17 After having excluded the presence of intracardiac shunt, 10 to 30 mL of agitated saline were injected into a peripheral vein. Appearance of a cloud of bubbles in the left atrium occurring at least three cardiac cycles after first appearance in the right atrium was considered confirmation of right-to-left pulmonary shunting because gas bubbles do not survive a normal capillary bed. The cardiologist performing the echocardiographic studies was blinded to the clinical history of patients and to the results of other diagnostic and laboratory tests.
Sex and age-related reference values for PASP, obtained by the same method, were reported by McQuillan et al. 18 Catheter-derived pulmonary artery pressure estimates were then proposed to the patients who showed clear clinical indications and was subsequently performed in case 1; the procedure was refused by cases 2 and 4.
Molecular analysis
DNA was obtained from peripheral blood after informed consent. Mutation analysis for ACVRL1 and ENG genes was performed according to Olivieri et al. 19 ; primers for exon amplification were obtained through the Genome Data Base 20 or designed by O.C. using Primer 3 Input Software. 21 Molecular analysis of the French patients was performed by L.G. as described in Lesca et al. 22 
RESULTS
A synopsis of TTE measurement of PASP and the patients' molecular results is included in Tables 2 and 3 ; the results from the French group are shown in Table 4 . The absence of tricuspid valve regurgitation prevented PASP measurement in 24 patients; this finding, associated with normal right ventricular morphology and normal 12-lead electrocardiogram (ECG), suggests normal right ventricular function, rendering PAH extremely unlikely in this subset of patients.
The PASP values observed in our group of patients with HHT (44 cases, mean: 30.83 Ϯ 7.87 mm Hg) were compared with the reference values for the different age groups from the large study by McQuillan et al. 18 (3790 controls: mean 28.3 Ϯ 4.9 mm Hg) and entered in Figure 1A (males) and B (females). No statistical tests were applied to the two groups because of the large difference in their size.
Nine unrelated patients with HHT (four females) showed PASP values higher than 1 standard deviation (SD) for their age group, and six of them (four females) had PASP values outside the 95% confidence interval (CI); seven of nine subjects (cases 1, 4, 7, 8, 9, 10, and 17) with elevated PASP values showed contrast echocardiographic evidence of right-to-left pulmonary shunting.
In case 1, a previously undiagnosed significant mitral stenosis plus regurgitation was first identified by echocardiography performed for the purposes of the present study; the increased value of PASP in this case was judged to be mostly secondary to the valvular abnormality, and this case was not considered in the analysis of results or in the discussion.
The involvement of BMPR2 was excluded in the only family whose size made it suitable for haplotype analysis (cases 10 -16, data not shown).
After the identification of mutations in exon 10 of ACVRL1 (Table 3) in two of nine subjects with increased PASP values, mutations that have already been reported in patients with HHT and PAH (Table 1) , [13] [14] [15] we tested PASP in six other patients with HHT carrying ACVRL1 exon 10 mutations, all of whom showed normal findings (Table 4 ) (MB in Lyon). Mutations found in either ENG or ACVRL1 are listed in Table 3 ; in 27 subjects, a mutation in ACVRL1 was found, whereas eight subjects (three of eight showing normal PASP values and five of eight with no tricuspid regurgitation, and thus nonmeasurable PASP) carried an ENG mutation.
Cases 10 to 16, in whom the R479X mutation in ACVRL1 was found, are relatives of a patient (not included in the present report) who was diagnosed with PAH and who underwent lung transplantation at age 20 years; the diagnosis of HHT was made only several years later. She belongs to a very large family (Ͼ50 people in the pedigree), and no diagnosis of PAH was proposed for any of her other relatives. Cases 12 and 13 (Table 2) are at the upper limit for PASP for their age group, and case 10 is above 1 SD; other relatives are fully within normal limits (cases 11, 14, and 15) or not measurable (case 16); these data are in keeping with the reduced penetrance of PAH due to the ACVRL1 mutation.
The mother of the index case in this family (case 16) at age 56 years showed no tricuspid regurgitation and normal ECG; similarly, case 15 (the mother of cases 12 and 13) at age 52 years was fully normal, whereas her daughters have PASP at ϩ1 SD compared with normal controls.
In our group of patients with HHT, we collected data from seven additional parent/child pairs: in five of them both parent and child were completely within normal limits or not measurable (cases 26 and 27; 36 and 37; 45 and 46; 48 and 49; 54 and 55; Table 2 ), whereas in two families (father/daughter and mother/daughter, cases 2 and 3, and 4 and 5, Table 2 ), the parent presented with a PASP value above the upper range limit, whereas their offspring showed PASP values within normal limits.
DISCUSSION
The association of PAH with HHT in the same family or the same subject was first reported by Trembath et al. 13 and subsequently confirmed by several authors 14, 15, 23 in 23 cases. All of the families in whom both PAH and HHT were present carried mutations in the ACVRL1 gene, and mutations or linkage to BMPR2 was consistently excluded. The 16 different mutations were scattered over several exons, but 11 of 16 were localized in exon 8 or 10 (Table 1) .
Three patients who carried an ENG mutation and showed PAH were reported as having a known intake of dexfenfluramine, a drug that is known to possibly cause PAH, or as having other well-known causes for increased pulmonary artery pressure 14, 24 ; a further case carrying a branch site mutation of ENG was recently reported by Harrison et al. 25 18 All cases or families reported up to now have been selected on the basis of a clinical diagnosis of PAH associated with symptoms of HHT.
In the course of a general clinical screening program on patients diagnosed with HHT according to Curaçao's criteria, 3 but who evidenced no clinical evidence of PAH, we obtained PASP data by using TTE in 44 of 68 patients.
This method is suitable for obtaining reliable estimates of PASP because the measurements obtained strictly correlate with those acquired by means of invasive procedures (concordance correlation coefficient 0.88, 95% CI 0.82-0.93). 16 Indeed, TTE has been considered a routine method for noninvasive PASP assessment by several other groups 26, 27 ; in addition, it makes it possible to obtain more general information on heart anatomy and function, including the right-sided chambers.
TTE proved useful in case 1, in whom a previously undiagnosed mitral valve disease was present; naturally, when the patient's cardiologic evaluation showed abnormalities that required further diagnostic steps, invasive procedures were also performed with consistent results (case 1, PASP 41 mm Hg by right-sided heart catheterization), as expected.
Overall, 8 of 44 patients (excluding case 1) (18.2%, three females) showed PASP values above 1 SD, and five of them were also above the upper 95% CI for age-related controls (Fig.  1A and B) .
Our results indicate that PASP values exceeding control values may be found in a relevant proportion ( Among patients with increased PASP values, five of nine also showed hepatic arteriovenous fistulae. These were of limited size and number (grade 1 or 2 according to Buscarini et al. 28 ) and did not cause a significant increase of right atrial flow as assessed both by normal appearance of the right atrial component of P wave on standard ECG and by absence of right atrial dilatation on TTE. Therefore, these fistulae do not seem to be related to the observed changes in PASP.
No data are currently available on the course of PASP levels in patients with HHT to assess whether these high values will increase over time to develop into a fully expressed PAH or not; on the basis of our results, we now recommend a yearly follow-up with TTE to all patients with PASP values at or above 1 SD over the mean; this is in agreement with the protocol suggested by Daniels et al. 27 for serendipitously diagnosed cases of mild asymptomatic pulmonary hypertension.
Estimated PASP values and mutation analysis in the family to which cases 10 to 16 belong (see "Results") are in keeping with the reduced penetrance of PAH due to ACVRL1 mutation and with previous observations of some families in whom the appearance of PAH may show age anticipation between generations. 29 On the basis of familial recurrence of PAH in families with HHT, we believe that patients with HHT such as cases 3 and 5 (with normal PASP values but one parent with increased values), should be offered the same follow-up as for subjects with confirmed increase of PASP values.
We also selected six additional patients solely on the basis of presence of mutations in exon 10 from the cohort of HHT cases reported by Lesca et al. 22 because this exon has frequently been reported (Table 1) to bear PAH-related mutations; however, in these additional cases TTE failed to demonstrate increased values of PASP (Table 4) .
Overall, we found more mutations in the ACVRL1 gene than in ENG (Table 3) ; this irregular distribution is in keeping with similar data provided by Lesca et al. 22 in the French population, and with our unpublished data on more than 100 index cases from among the Italian population.
The distribution of mutations of the ACVRL1 gene in HHT/ PAH is peculiar in the sense that 11 of 16 reported mutations (68.8%) are localized in exons 8 and 10; these two exons contain only 30% to 35% of the variously reported mutations when taking into consideration the reviews by Abdalla and Letarte, 30 and van den Driesche et al., 31 the data by Lesca et al., 22 and our unpublished results.
Among the mutations we found in patients with HHT with increased PASP (Table 3) , two of six are in exon 10 and have already been described in patients with PAH and HHT; the others are in exon 8, and one of them was previously unreported.
Mutations occurring in exon 8 frequently cause the modification of an arginine residue; R437 and R411 have so far been involved five times and are thus likely to be mutation hot spots. The possible mechanism to explain the frequent involvement of arginine residues has been discussed by Abdalla et al. 32 Exon 10 contains the NANDOR BOX, relevant for the regulation of TGFbeta signaling, 15, 33 and four of six mutations fell into this region, as did the two mutations we observed where codon 479 was more frequently involved.
The only known mutation of exon 5 of ACVRL1 was observed in a patient with PAH who did not, however, show any clinical signs or have a family history of HHT. 14 At present, PAH was observed only in association with HHT2; this observation, if confirmed, would be a defined genotype-phenotype correlation for ACVRL1 mutations.
It is clearly essential to document more cases to verify whether mutations in exons 8 and 10 in general, or those previously discussed in particular, possibly constitute a specific genetic risk factor for developing PAH.
In our group of patients with HHT, if we exclude all the cases from the family with a single known patient affected with PAH together with case 1, we still have 5 of 37 (13.5%) cases with PASP values of the normal range; this suggests that this seemingly abnormal finding may in fact be much more common than previously thought. Thus our data add confirmatory evidence to recent reports by Harrison et al. 14 and Abdalla et al. 15 demonstrating that PAH should be considered a possible severe complication in the course of HHT.
Presently, TTE is being used in the routine clinical workup of patients affected by HHT to assess the presence of lung AVMs. We believe that PASP measurement should also be attempted in all HHT cases, and certainly in those patients carrying mutations previously demonstrated to be associated with PAH.
TTE is a noninvasive test, well tolerated by patients, that can even be safely performed in children, a relevant point in view of the increasing number of cases of PAH observed in pediatric age, 25, 13, 29 and in light of the possible anticipation of symptoms.
In conclusion, the pathway by which ENG and ACVRL1 regulate transforming growth factor-beta signaling includes a large number of genes and proteins; it is therefore highly likely that other unreported associations between HHT and apparently unrelated diseases may be discovered in the future by means of a more careful and focused clinical examination of large series of patients.
